BioWa and Lonza to generate production platform for more potent antibodies
US-based BioWa, a wholly owned subsidiary of Kyowa Hakko Kogyo Co., of Japan, and Swiss company Lonza have signed a strategic research collaboration agreement to combine BioWa's Potelligent technology with Lonza's GS Gene Expression System and CHOK1SV cell line.
US-based BioWa, a wholly owned subsidiary of Kyowa Hakko Kogyo Co., of Japan, and Swiss company Lonza have signed a strategic research collaboration agreement to combine BioWa's Potelligent technology with Lonza's GS Gene Expression System and CHOK1SV cell line.
This is expected to generate a new technology platform to produce more potent antibodies with greatly enhanced antibody-dependent cellular cytotoxicity (ADCC) in a high-yield mammalian expression system for industry-wide use.
Under the terms of the agreement, the parties intend to make the new Potelligent CHOK1SV cell line available for licensing and it will be offered as part of Lonza's development services in combination with Lonza's GS Gene Expression System. Details of financial terms were not disclosed.
"This collaboration with Lonza will enable us to jointly offer a superior production platform to parties interested in the development of efficacy-enhanced antibody therapeutics," said Dr Masamichi Koike, BioWa's president and ceo.. "We believe that combining both parties" technologies addresses a clear market need to improve production yields and can significantly aid the development of more effective targeted treatments for cancer and other life-threatening and debilitating diseases."
The two companies will jointly market the new technology platform.
